Tag: immunotherapy for hepatocellular carcinoma

Home / immunotherapy for hepatocellular carcinoma

Categories

Nivolumab with ipilimumab is approved by the USFDA for unresectable or metastatic hepatocellular carcinoma

On April 11, 2025, the Food and Drug Administration sanctioned nivolumab (Opdivo, Bristol Myers Squibb Company) in conjunction with ipilimumab (Yervoy, Bristol Myers Squibb Company) for the first trea...
immunotherapy-for-hepatocellular-carcinoma

Scan the code